Congress Maintains Historic Funding for Prostate Cancer Research September 14, 2018 WASHINGTON, D.C. – Tonight the U.S. Senate and House released their conference report on the 2019 Defense Appropriations Bill, which once again allocates $100M to the Prostate Cancer Research Program (PCRP). A year ago, Congress increased the PCRP at the Department of Defense (DoD) budget by $10M, returning the program to its 2001 funding level for the first time in 18 years.“This is the first time ever the PCRP has been at $100M in back-to-back years,” said ZERO CEO Jamie Bearse. “Thank you to our tireless advocates for delivering on a brighter future for men and their families fighting prostate cancer. These funds will lead to new groundbreaking treatments and diagnostic tools.”Hundreds of passionate advocates spent countless hours meeting with their elected officials through ZERO’s Summit in Washington, D.C. on a cold February day, then across telephone lines this spring, and by pounding the pavement during a hot August recess period by attending in-district meetings. Increasing research funds at the PCRP is at the top of ZERO’s Summit agenda because the program uniquely works with patients to identify gaps in research and care then awards talented scientists who are pursuing advancements to eliminate those identified areas of need.The research funded by the PCRP is more critical than ever as Surveillance, Epidemiology, and End Results (SEER) data from the National Cancer Institute predicted deaths to jump by 3,000 in 2018 alone. More than 164,000 men will be diagnosed with prostate cancer this year and nearly ten percent of those diagnoses will occur among our nation’s veteran population. In fact, prostate cancer is the most frequently diagnosed cancer among male veterans.Next the bill will go to the House and Senate for a vote before being approved by the Administration. Press Release
WASHINGTON, D.C. – Tonight the U.S. Senate and House released their conference report on the 2019 Defense Appropriations Bill, which once again allocates $100M to the Prostate Cancer Research Program (PCRP). A year ago, Congress increased the PCRP at the Department of Defense (DoD) budget by $10M, returning the program to its 2001 funding level for the first time in 18 years.“This is the first time ever the PCRP has been at $100M in back-to-back years,” said ZERO CEO Jamie Bearse. “Thank you to our tireless advocates for delivering on a brighter future for men and their families fighting prostate cancer. These funds will lead to new groundbreaking treatments and diagnostic tools.”Hundreds of passionate advocates spent countless hours meeting with their elected officials through ZERO’s Summit in Washington, D.C. on a cold February day, then across telephone lines this spring, and by pounding the pavement during a hot August recess period by attending in-district meetings. Increasing research funds at the PCRP is at the top of ZERO’s Summit agenda because the program uniquely works with patients to identify gaps in research and care then awards talented scientists who are pursuing advancements to eliminate those identified areas of need.The research funded by the PCRP is more critical than ever as Surveillance, Epidemiology, and End Results (SEER) data from the National Cancer Institute predicted deaths to jump by 3,000 in 2018 alone. More than 164,000 men will be diagnosed with prostate cancer this year and nearly ten percent of those diagnoses will occur among our nation’s veteran population. In fact, prostate cancer is the most frequently diagnosed cancer among male veterans.Next the bill will go to the House and Senate for a vote before being approved by the Administration.
